Featured Research

from universities, journals, and other organizations

Molecular imaging for Alzheimer's disease may be available in hospitals within a year, studies suggest

Date:
June 11, 2011
Source:
Society of Nuclear Medicine
Summary:
Researchers the world over are advancing positron emission tomography as an effective method of early detection for Alzheimer's disease, a currently incurable and deadly neurological disorder. Three studies are providing new insights into the development of Alzheimer's disease while opening the door to future clinical screening and treatments.

Researchers the world over are advancing positron emission tomography (PET) as an effective method of early detection for Alzheimer's disease, a currently incurable and deadly neurological disorder. Three studies presented at SNM's 58th Annual Meeting are providing new insights into the development of Alzheimer's disease while opening the door to future clinical screening and treatments.

According to the World Health Organization, an estimated 18 million people worldwide are currently living with Alzheimer's disease -- a number projected to almost double by 2025.

"The aging population around the world is escalating exponentially. From a macro perspective, amyloid imaging with PET scans can help to ascertain the likelihood that individuals will deteriorate cognitively within a few years, thereby enabling more efficient channeling of health care resources," says Kevin Ong, MD, lead author of a presented study and a research scientist at Austin Hospital, Melbourne, Australia. "From a micro perspective, planning and lifestyle modifications are possible for individuals who seek screening for Alzheimer's disease."

Molecular imaging of Alzheimer's disease is focused on detecting and analyzing the formation of a naturally occurring protein in the brain called beta-amyloid, which researchers now say is directly involved in the pathology of Alzheimer's.

"It turns out that increased amyloid is bad for cognition even in the healthy elderly," says Michael Devous, Sr., PhD, director of neuroimaging for the Alzheimer's Disease Center at UT Southwestern Medical Center, Dallas, Texas. "If you look at working memory, processing speed or fluent reasoning, three critical general domains of cognition, the more amyloid you have the worse your performance, and that's after correcting for age."

Not only is this important for imaging the disease, but it may also prove to be the key to amyloid-associated therapies and vaccines. Investigators warn that the beginning stages of the disease can precede symptoms of dementia as much as a decade or more. Imaging patients when they first show signs of mild cognitive impairment could be essential to determining their risk of future disease.

"For individuals who have already developed a measurable memory decline, a positive scan for amyloid is the most accurate predictor of progression to Alzheimer's disease," said Christopher Rowe, MD, a lead investigator for the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging and professor of nuclear medicine at Austin Hospital, Victoria, Australia. "Amyloid imaging with PET scans is expected to be widely available soon for clinical practice. It will be an important new tool in the assessment of cognitive decline."

Beta-amyloid accumulates as neurotoxic plaque in individuals preceding the onset of Alzheimer's disease, and as a result, extensive neural tissues that control major mental and physical functioning -- including memory, language and motor function -- are decimated. In time the disease becomes debilitating and has a devastating impact on individuals' quality of life.

Three ongoing studies presented at this year's meeting involve several years of research based on hundreds of participants ranging widely in age, cognitive ability and stage of disease. Results of these studies show that amyloid plaques build up very slowly, by an estimated two to three percent per year, and that they are often already present in healthy older individuals -- 12 percent of those in their 60s, 30 percent of those in their 70s and 55 percent in those over the age of 80. In one study, about 25 percent of subjects over the age of 60 had amyloid plaques. The presence of significant amyloid buildup is linked to quicker memory decline and brain atrophy.

One of the major questions in Alzheimer's imaging has been which imaging agent is best for amyloid plaque screening. Several studies have been conducted using 11C Pittsburgh Compound-B (11C-PIB), a PET imaging agent that binds to beta-amyloid in neural tissues, but two of the current studies are gauging the benefit of using F-18 labeled tracers (F-18 Florbetaben and F-18 Florbetapir), designed for routine clinical use. Both F-18 Florbetaben and F-18 Florbetapir are proving to be good predictors of progression to Alzheimer's disease, and F-18 amyloid imaging agents are the likeliest agents to move forward into clinical practice in the near future.

Researchers estimate that amyloid imaging agents will be available for clinical use in fewer than 12 months. These and further studies will continue to amass data about the development of Alzheimer's disease, and potential treatments could eventually stop and perhaps even prevent or reverse damage in the brain caused by Alzheimer's disease.


Story Source:

The above story is based on materials provided by Society of Nuclear Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Society of Nuclear Medicine. "Molecular imaging for Alzheimer's disease may be available in hospitals within a year, studies suggest." ScienceDaily. ScienceDaily, 11 June 2011. <www.sciencedaily.com/releases/2011/06/110606131707.htm>.
Society of Nuclear Medicine. (2011, June 11). Molecular imaging for Alzheimer's disease may be available in hospitals within a year, studies suggest. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2011/06/110606131707.htm
Society of Nuclear Medicine. "Molecular imaging for Alzheimer's disease may be available in hospitals within a year, studies suggest." ScienceDaily. www.sciencedaily.com/releases/2011/06/110606131707.htm (accessed September 18, 2014).

Share This



More Mind & Brain News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Corporal Punishment on Decline, Debate Renews

Corporal Punishment on Decline, Debate Renews

AP (Sep. 16, 2014) Corporal punishment in the United States is on the decline, but there is renewed debate over its use after Minnesota Vikings running back Adrian Peterson was charged with child abuse. (Sept. 16) Video provided by AP
Powered by NewsLook.com
FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com
Shocker: Journalists Are Utterly Addicted To Coffee

Shocker: Journalists Are Utterly Addicted To Coffee

Newsy (Sep. 13, 2014) A U.K. survey found that journalists consumed the most amount of coffee, but that's only the tip of the coffee-related statistics iceberg. Video provided by Newsy
Powered by NewsLook.com
'Magic Mushrooms' Could Help Smokers Quit

'Magic Mushrooms' Could Help Smokers Quit

Newsy (Sep. 11, 2014) In a small study, researchers found that the majority of long-time smokers quit after taking psilocybin pills and undergoing therapy sessions. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins